Business Wire

VALBIOTIS

21.9.2020 07:37:09 CEST | Business Wire | Press release

Share
VALBIOTIS Selected to Present 3 Studies on TOTUM-63 by the European Association for the Study of Diabetes (EASD)

Regulatory News:

VALBIOTIS (Paris:ALVAL) (FR0013254851 - ALVAL, eligible for the PEA/SME), a Research & Development company committed to scientific innovation for preventing and combating metabolic diseases, announces the selection of 3 studies on TOTUM-63 by the European Association for the Study of Diabetes (EASD), which will be presented at the association's annual meeting in September 2020.

For the third consecutive year, VALBIOTIS has seen its results on TOTUM-63, its active substance designed to reduce the risk of type 2 diabetes, selected by the main European diabetes meeting. This year, VALBIOTIS will present 3 studies at this major event, to be held from 22 to 25 September in virtual format due to the COVID-19 pandemic.

The clinical results of the international Phase II study of TOTUM-63 will first be presented by Prof. Jean-Marie Bard in the form of an e-poster (Abstract #621). Completed in the summer of 2019, this study showed a significant reduction in the main risk factors for type 2 diabetes (glycemic parameters, waist circumference, body weight) in prediabetic people, compared to a placebo. Already selected by the American Diabetes Association last June, these results have now been accepted by the two main scientific societies in the field of diabetes worldwide.

Murielle CAZAUBIEL, member of the Management Board and Director of Development and Medical Affairs at VALBIOTIS, comments: "The excellent results of the TOTUM-63 Phase II clinical study exceeded our expectations and enabled us to enter into a strategic partnership with Nestlé Health Science last February. In 2020, we have launched a strategy for the scientific communication of these results, which has already led to selection for presentations at the two largest diabetes meetings in the world, the ADA and EASD, within three months. These publications constitute indisputable recognition of the quality of our work. They are also a great source of pride and an additional incentive to complete the clinical development of TOTUM-63 with our partner Nestlé Health Science."

In addition to these clinical results, two preclinical studies demonstrating the positive effects of TOTUM-63 on obesity and carbohydrate metabolism disorders have also been selected by the EASD (Abstract #448 and #623). These studies highlight the efficacy of TOTUM-63 through two protocols: a protocol for the prevention of weight gain and associated metabolic disorders, carried out by the VALBIOTIS teams, and a protocol for the management of obesity and acquired disorders, carried out by the team of Dr Bruno Guigas (University of Leiden, Netherlands) with Vanderbilt University (Nashville, USA), one of the American expert centers for the study of diabetes. This preclinical work shows a reduction in body weight thanks to TOTUM-63 as well as an improvement in carbohydrate parameters in both protocols. It also provides a better understanding of the multi-targeted mode of action of TOTUM-63: reduced intestinal absorption of lipids and glucose, increased sensitivity of peripheral tissues to insulin and increased energy expenditure.

Pascal SIRVENT, member of the Management Board, Director of Discovery, Preclinical and Translational Research, states: "Since 2014, we have been conducting extensive preclinical work on TOTUM-63 in partnership with French and international universities, such as Leiden (the Netherlands) or Vanderbilt (USA) universities. These additional studies are essential, as they guide the clinical development of the active substances and document their mode of action. The two studies selected have demonstrated promising additional effects on the prevention and reversal of weight gain and its consequences on carbohydrate metabolism. We are now very proud to present them to the European diabetology community."

The three VALBIOTIS presentations at the EASD 2020 meeting are available at www.valbiotis.com/scientific-publications .

ABOUT TOTUM-63
TOTUM-63 is a unique and patented combination of 5 plant extracts that targets the physiopathological mechanisms of type 2 diabetes.
TOTUM-63 has already been shown to be safe and effective in healthy volunteers in a Phase I/II clinical study. Results of an international randomized, placebo-controlled Phase II study showed that TOTUM-63 reduced fasting and 2-hour blood glucose levels, two risk factors for type 2 diabetes, compared to placebo. In these subjects, who also had abdominal obesity, TOTUM-63 also significantly reduced body weight and waist circumference.
TOTUM-63 benefits from intellectual property that has been validated by the granting of patents in the main world markets: Europe (covering 39 countries), the United States and Russia, and national phases are underway in more than 20 countries including China, Japan, Brazil and Australia. TOTUM-63's industrial production capacity, in accordance with North American and European standards, has been validated. TOTUM-63 already has marketing authorizations linked to its status in Europe.
In February 2020, VALBIOTIS signed a long-term global strategic partnership with Nestlé Health Science for the development and worldwide marketing of TOTUM-63. This unique partnership in the field of Health Nutrition provides for the worldwide marketing of TOTUM-63 by Nestlé Health Science, possibly before obtaining a health claim depending on the region. It will also finance the final stages of development of TOTUM-63.

ABOUT VALBIOTIS
VALBIOTIS is a Research & Development company committed to scientific innovation for preventing and combating metabolic diseases in response to unmet medical needs.
VALBIOTIS has adopted an innovative approach, aiming to revolutionize healthcare by developing a new class of nutritional health solutions designed to reduce the risk of major metabolic diseases, based on a multi-target approach and made possible by the use of plant-based ingredients.
Its products are intended to be licensed to players in the health world.
VALBIOTIS was founded in La Rochelle in early 2014 and has formed numerous partnerships with top academic centers. The Company has established three sites in France – Périgny, La Rochelle (17) and Riom (63).
VALBIOTIS is a member of the “BPI Excellence” network and received “Innovative Company“ status awarded by BPI France. Valbiotis has also been awarded “Young Innovative Company” status and has received major financial support from the European Union for its research programs via the European Regional Development Fund (ERDF). VALBIOTIS is a PEA-SME eligible company.
Find out more about VALBIOTIS: www.valbiotis.com

Name: VALBIOTIS
ISIN code: FR0013254851
Mnemonic code: ALVAL

DISCLAIMER
This press release contains forward-looking statements about VALBIOTIS’ objectives, based on rational hypotheses and the information available to the company at the present time. However, in no way does this constitute a guarantee of future performance, and these projections may be affected by changes in economic conditions and financial markets, as well as a certain number of risks and uncertainties, including those described in the VALBIOTIS registration document, filed with the French Financial Markets Regulator (AMF) on 31 July 2020 (application number R 120--018). This document is available on the Company’s website (www.valbiotis.com ).

This press release, as well as the information contained herein, does not constitute an offer to sell or subscribe to, or a solicitation to purchase or subscribe to, VALBIOTIS’ shares or securities in any country.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

What Our Pupils Reveal: MindMetrix Joins Wyss Geneva to Bring Eye-Based Biofeedback to Mental Health16.11.2026 15:45:00 CET | Press release

We are proud to welcome MindMetrix AG as one of the newest Wyss Geneva ventures. Born out of research at ETH Zurich’s Neural Control of Movement Lab, MindMetrix is a neurotechnology company that reads the brain’s arousal system through the eyes and turns it into live biofeedback, so people can see, and learn to regulate, their own mental state. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261116303495/en/ MindMetrix’s myflow platform turns pupil-based measurements into live biofeedback, with each user’s training sessions and progress shown in a dashboard. Image: MindMetrix The mind is still assessed mostly through questionnaires and self-report, with no objective, real-time measure of brain activity. The size of our pupils changes with the brain’s arousal center, a tiny region deep in the brainstem that is otherwise hard to observe without a brain scan. MindMetrix uses pupillometry to read that signal and turn it into live

Factbird Launches Visual Intelligence and Factbird MCP: AI That Sees the Shop Floor and Connects to Any AI Assistant16.11.2026 15:39:00 CET | Press release

Two new AI capabilities, available now. Visual Intelligence turns camera footage into production data. Factbird MCP gives AI assistants direct access to production data in Factbird. Today, Factbird announces the launch of two new AI capabilities. Visual Intelligence uses cameras and AI to measure what sensors and PLCs miss. Factbird MCP lets AI assistants such as Claude, ChatGPT, and Microsoft Copilot work directly with production data in Factbird. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261113769016/en/ Factbird Visual Intelligence tracking a bottling line in real time, showing filler and shrink wrapper status, line speed of 72 bottles per minute, and operator activity around the line. (AI-generated illustration) The losses that are hardest to explain happen around the machine. A station waits for material. A manual task runs long on the night shift. Each one costs a few minutes, and over a year they add up to real c

Argenta and Loyal Announce Partnership to Advance LOY-003, Loyal's Lifespan-Extension Candidate for Large-Breed Dogs16.11.2026 15:17:00 CET | Press release

Collaboration brings together Argenta's Molecule to Market capabilities and Loyal’s lifespan extension therapeutics with early development of LOY-003 Argenta, the global contract development, research and manufacturing organization (CDRMO) dedicated exclusively to animal health, and Loyal, the clinical-stage animal health company pioneering the first lifespan extension drugs for dogs, today announced a strategic partnership under which Argenta will support early-stage development of LOY-003, Loyal's investigational candidate for large-breed dog lifespan extension. The collaboration will focus on early development of the drug, with the potential to expand as the program advances. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261116891949/en/ Founded by CEO Celine Halioua, Loyal is working to bring the first FDA-approved lifespan extension drugs to market for dogs. The company's pipeline includes three investigational candida

NIKE, Inc. Unveils the Next Generation of Innovation Across Performance Sports and Sportswear16.11.2026 15:08:00 CET | Press release

From the next evolution of Nike Air to new Nike Mind and Nike Free footwear, Nike is solving distinct athlete needs — and creating platforms that can bring those breakthroughs to more athletes.New innovations and platforms span running, training, basketball, football and outdoor sports, reflecting Nike's focus on delivering best-in-class performance to athletes across disciplines.Nike is bringing performance innovation into everyday style, reinventing the classics athletes love while introducing new silhouettes, including Project Ride and Nike Morpho X.Much of what Nike is showing arrives over the coming year, with some innovations following later. Watch for more details in the months to come. NIKE, Inc. (NYSE: NKE) is sharing a first look at its next generation of innovation, showcasing new technologies, product platforms and silhouettes across footwear, Sportswear and performance apparel. This press release features multimedia. View the full release here: https://www.businesswire.com

2027 Cocktail Trends Put a Fresh Spin on Classics, Flavor and the Night Out16.11.2026 13:00:00 CET | Press release

The Bacardi Cocktail Trends Report explores how flavor, hospitality and human recommendations will shape the drinks experience The five emerging movements poised to shape cocktail culture in 2027 were unveiled today in the eighth annual Bacardi Cocktail Trends Report published by Bacardi Limited, the world’s largest privately held international spirits company. Created in collaboration with strategic foresight consultancy The Future Laboratory (TFL), the report combines global consumer research, bartender insights, and industry perspectives to explore how the cocktail experience is evolving. The report also reveals the top cocktails Legal Drinking Age (LDA) consumers plan to order at bars and venues worldwide throughout 2027. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261116061749/en/ The Bacardi Cocktail Trends Report explores how flavor, hospitality and human recommendations will shape the drinks experience in 2027. “F

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye